GILD Insider Trading

Insider Ownership Percentage: 0.27%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $75,841,935.55

Gilead Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$266ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Gilead Sciences Share Price & Price History

Current Price: $104.49
Price Change: Price Decrease of -0.392 (-0.37%)
As of 04/17/2025 04:59 PM ET

This chart shows the closing price history over time for GILD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$104.49Closing price on 04/18/25:

SEC Filings (Institutional Ownership Changes) for Gilead Sciences (NASDAQ:GILD)

83.67% of Gilead Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GILD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$395Mbought$223MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40B-$20B$0$20B$40BTotal InflowsTotal Outflows
Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More on Gilead Sciences

Today's Range

Now: $104.49
Low: $103.52
High: $105.75

50 Day Range

MA: $109.16
Low: $101.40
High: $117.41

52 Week Range

Now: $104.49
Low: $62.07
High: $119.96

Volume

8,066,368 shs

Average Volume

7,519,796 shs

Market Capitalization

$130.10 billion

P/E Ratio

282.40

Dividend Yield

2.99%

Beta

0.32

Who are the company insiders with the largest holdings of Gilead Sciences?

Gilead Sciences' top insider investors include:
  1. Andrew D Dickinson (CFO)
  2. Johanna Mercier (Insider)
  3. Merdad Parsey (Insider)
  4. Jeffrey Bluestone (Director)
Learn More about top insider investors at Gilead Sciences.

Who are the major institutional investors of Gilead Sciences?

Gilead Sciences' top institutional investors include:
  1. GAMMA Investing LLC — 0.20%
  2. Rhumbline Advisers — 0.18%
  3. Handelsbanken Fonder AB — 0.09%
  4. Confluence Investment Management LLC — 0.08%
  5. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH — 0.04%
  6. Mn Services Vermogensbeheer B.V. — 0.04%
Learn More about top institutional investors of Gilead Sciences stock.

Which institutional investors are selling Gilead Sciences stock?

During the last quarter, GILD stock was sold by these institutional investors:
  1. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH
  2. IMC Chicago LLC
  3. Assenagon Asset Management S.A.
  4. Exchange Traded Concepts LLC
  5. Confluence Investment Management LLC
  6. Foundation Resource Management Inc.
  7. Thomasville National Bank
  8. Lmcg Investments LLC
In the last year, company insiders that have sold Gilead Sciences company stock include:
  1. Andrew D Dickinson (CFO)
  2. Johanna Mercier (Insider)
  3. Merdad Parsey (Insider)
  4. Jeffrey Bluestone (Director)
Learn More investors selling Gilead Sciences stock.

Which institutional investors are buying Gilead Sciences stock?

Within the previous quarter, GILD stock was bought by institutional investors including:
  1. GAMMA Investing LLC
  2. Handelsbanken Fonder AB
  3. Sapient Capital LLC
  4. Fifth Third Bancorp
  5. Unigestion Holding SA
  6. Milestone Asset Management LLC
  7. Abacus FCF Advisors LLC
  8. Transform Wealth LLC